Novartis Poised To Grow Despite $9bn In LOEs Coming, CEO Says
Executive Summary
CEO Vas Narasimhan committed to delivering compound annual growth of 4% from 2020-2026, driven by newer brands plus some pipeline assets.
You may also be interested in...
Novartis MS Franchise Boosted After Fending Off Last Gilenya Challenge
The Swiss firm expects no generic versions of Gilenya in the US market "for at least the next two years" after a court again ruled against HEC Pharma, the only remaining company challenging its patent.
Novartis Plumps For Share Buybacks Before Bolt-On M&A
The Basel-headquartered giant has decided to spend a major chunk of its $20.7bn windfall from the sale of its stake in Roche on a stock repurchasing program up to the end of 2023, disappointing some observers who wanted to see big licensing deals or acquisitions.
Novartis Will Co-Develop UCB’s Alpha-Syn Inhibitor For Parkinson’s
Deal Snapshot: Seeking to bring a disease-modifying Parkinson’s drug to market, Novartis will team with UCB on developing and commercializing UCB0599, a Phase II oral alpha-synuclein inhibitor.